(Q35179563)

7 August 2017

1 reference

title

Diagnosis, prevention, and intervention for the metabolic syndrome (English)

1 reference

7 August 2017

1 reference

1 reference

Cranford L Scott

1

1 reference

PubMed ID

12867253

7 August 2017

language of work or name

English

0 references

publication date

1 July 2003

1 reference

American Journal of Cardiology

7 August 2017

1 reference

7 August 2017

92

1 reference

7 August 2017

35i-42i

1 reference

7 August 2017

1A

1 reference

Clustering of heart disease risk factors in diabetic compared to nondiabetic adults

7 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900507-1

Banting lecture 1988. Role of insulin resistance in human disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900507-1

Connections between obesity and dyslipidaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900507-1

Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900507-1

Cardiovascular morbidity and mortality associated with the metabolic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900507-1

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900507-1

Prevalence of insulin resistance in metabolic disorders: the Bruneck Study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900507-1

Prevalence of the metabolic syndrome in drug-treated hypertensive patients and control subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900507-1

Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900507-1

Hyperinsulinemia as an independent risk factor for ischemic heart disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900507-1

Distribution of adipose tissue and risk of cardiovascular disease and death: a 12 year follow up of participants in the population study of women in Gothenburg, Sweden.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900507-1

Abdominal adipose tissue distribution, obesity, and risk of cardiovascular disease and death: 13 year follow up of participants in the study of men born in 1913.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900507-1

The influence of body fat distribution on the incidence of diabetes mellitus. 13.5 years of follow-up of the participants in the study of men born in 1913.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900507-1

The dense LDL phenotype. Association with plasma lipoprotein levels, visceral obesity, and hyperinsulinemia in men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900507-1

Diabetes, hypertension, and cardiovascular disease: an update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900507-1

Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900507-1

Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900507-1

Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900507-1

Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900507-1

Dysglycaemia and risk of cardiovascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900507-1

Homozygosity for a new mutation (Ile119-->Met) in the insulin receptor gene in five sibs with familial insulin resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900507-1

Insulin-receptor gene and its expression in patients with insulin resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900507-1

Linkage of chromosomal markers on 4q with a putative gene determining maximal insulin action in Pima Indians

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900507-1

An amino acid substitution in the human intestinal fatty acid binding protein is associated with increased fatty acid binding, increased fat oxidation, and insulin resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900507-1

Quantitative trait loci for cellular defects in glucose and fatty acid metabolism in hypertensive rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900507-1

Adaptation and maladaptation of the heart in diabetes: Part I: general concepts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900507-1

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900507-1

Hypertension and associated metabolic abnormalities--the role of insulin resistance and the sympathoadrenal system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900507-1

Phospholipid transfer protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900507-1

A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900507-1

Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900507-1

Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900507-1

Triglycerides and atherogenic lipoproteins: rationale for lipid management

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900507-1

Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900507-1

Hepatic lipase as a focal point for the development and treatment of coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900507-1

Insulin-mediated skeletal muscle vasodilation contributes to both insulin sensitivity and responsiveness in lean humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900507-1

Prevention Conference VI: Diabetes and Cardiovascular Disease: executive summary: conference proceeding for healthcare professionals from a special writing group of the American Heart Association

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900507-1

Risk variable clustering in the insulin resistance syndrome. The Framingham Offspring Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900507-1

Microalbuminuria precedes the development of NIDDM

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900507-1

Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900507-1

Ramipril and the development of diabetes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900507-1

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900507-1

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900507-1

Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900507-1

TRIPOD (TRoglitazone In the Prevention Of Diabetes): a randomized, placebo-controlled trial of troglitazone in women with prior gestational diabetes mellitus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900507-1

The STOP-NIDDM Trial: an international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data. Study to Prevent Non-Insuli

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900507-1

Rationale and design of a secondary prevention trial of lowering normal plasma cholesterol levels after acute myocardial infarction: The cholesterol and recurrent events trial (CARE)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900507-1

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900507-1

Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900507-1

Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900507-1

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900507-1

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900507-1

The use of fibrates and of statins in preventing atherosclerosis in diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900507-1

Metabolic and additional vascular effects of thiazolidinediones.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900507-1

Addressing the insulin resistance syndrome: a role for the thiazolidinediones

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900507-1

Rationale for and role of thiazolidinediones in type 2 diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900507-1

Current concepts in insulin resistance, type 2 diabetes mellitus, and the metabolic syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900507-1

Defining specific goals of therapy in treating dyslipidemia in the patient with low high-density lipoprotein cholesterol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900507-1

A transgenic model of visceral obesity and the metabolic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900507-1

10.1016/S0002-9149(03)00507-1

7 January 2021

Identifiers

DOI

1 reference

7 August 2017

1 reference

PubMed ID

12867253